Literature DB >> 7631148

Constitutive and inducible cytokine mRNA expression in the human mast cell line HMC-1.

G Nilsson1, V Svensson, K Nilsson.   

Abstract

The discovery that mast cells are a potential source of cytokines has suggested new ways in which mast cells can act in immunological and inflammatory responses. In this study we have used the HMC-1 cell line as a model for human mast cells to study the constitutive and inducible mRNA expression of interleukins, colony-stimulating factors, interferons, tumour necrosis factors alpha and beta, tumour growth factor beta and platelet-derived growth factor A and B. We found that HMC-1 cells constitutively expressed mRNA for TNF-alpha and TGF-beta, and a low level of M-CSF. After treatment with the phorbol ester TPA or the calcium ionophore ionomycin expression of several cytokines, i.e. IL-1 beta, IL-3, IL-6, GM-CSF, TNF-beta and PDGF-A, could be detected. Both TPA and ionomycin induced the same set of cytokines, but the effect of TPA was more prominent. The relative induction was calculated to be 70X for IL-1 beta and IL-3, 30X for GM-CSF and PDGF-A and 3 - 10X for IL-6, M-CSF and TNF-beta. This study shows that human mast cells have the capacity to express not only cytokines mediating an immune response but also cytokines affecting other cell types, e.g. fibroblasts and endothelial cells, involved in later steps of the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631148     DOI: 10.1111/j.1365-3083.1995.tb03628.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

1.  Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line.

Authors:  C A King; J S Marshall; H Alshurafa; R Anderson
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  Importance of mast cells in the pathophysiology of asthma.

Authors:  Seong H Cho; Andrea J Anderson; Chad K Oh
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

3.  Characterization of Mast Cell Activation Syndrome.

Authors:  Lawrence B Afrin; Sally Self; Jeremiah Menk; John Lazarchick
Journal:  Am J Med Sci       Date:  2016-12-16       Impact factor: 2.378

4.  Role of mast cells and myofibroblasts in human peritoneal adhesion formation.

Authors:  Xiang Xu; Avraham Rivkind; Orit Pappo; Alon Pikarsky; Francesca Levi-Schaffer
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

5.  The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus.

Authors:  G O Elpek; T Gelen; N H Aksoy; A Erdoğan; L Dertsiz; A Demircan; N Keleş
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

6.  Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor.

Authors:  R J Blair; H Meng; M J Marchese; S Ren; L B Schwartz; M G Tonnesen; B L Gruber
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

7.  Prognostic value of tumor-infiltrating mast cells in outcome of patients with esophagus squamous cell carcinoma.

Authors:  Ashraf Fakhrjou; Seid Mahdi Niroumand-Oscoei; Mohamad Hosein Somi; Morteza Ghojazadeh; Shahnaz Naghashi; Shabnam Samankan
Journal:  J Gastrointest Cancer       Date:  2014-03

8.  Characterization of gene expression in resting and activated mast cells.

Authors:  H Chen; M Centola; S F Altschul; H Metzger
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

9.  Comparative cytokine gene expression: regulation and release by human mast cells.

Authors:  A Möller; B M Henz; A Grützkau; U Lippert; Y Aragane; T Schwarz; S Krüger-Krasagakes
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

10.  Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor.

Authors:  M-M Suttle; G Nilsson; E Snellman; I T Harvima
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.